GenoMed Seeks Volunteers with Diabetes
ST. LOUIS, Jan. 17 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based genomics company, announced today that it is seeking volunteers with diabetes to see if its new treatment approach will delay all complications of diabetes.
GenoMed has discovered that an extremely safe class of drugs called ACE inhibitors may be useful for many serious diseases, including all complications of diabetes. ACE stands for "angiotensin converting enzyme."
GenoMed has found that patients with complications of either type 1 ("juvenile onset") or type 2 ("adult onset") diabetes tend to have overactivity of their ACE enzyme. This includes eye disease ("retinopathy") and nerve disease ("neuropathy"), as well as kidney disease. A logical approach is to inhibit ACE effectively in all patients with diabetes to prevent complications.
The research supporting this new treatment approach was published in the fall, 2002 in Diabetes Technology and Therapeutics.
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease.
To volunteer, please contact GenoMed's Chief Medical Officer, Dr. David Moskowitz, tel. 314-977-0110, fax 928-395-2580, email: dwmoskowitz@genomedics.com or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Dr. David Moskowitz, Chief Medical Officer of GenoMed, Inc.,
+1-314-977-0110, or fax, +1-928-395-2580, or dwmoskowitz@genomedics.com/
Web site: genomedics.com |
